Tuesday, 22 May 2018
Latest news
Main » Coherus Biosciences Inc (CHRS) PT Set at $38.00 by Citigroup Inc

Coherus Biosciences Inc (CHRS) PT Set at $38.00 by Citigroup Inc

19 May 2017

"Amgen (as expected) filed suit against Coherus claiming violations of the Neulasta Patent '707 (purification process).", the firm's analyst wrote.

A number of other equities analysts have also recently issued reports on the stock.

02/01/2017 - Coherus BioSciences, Inc. had its " rating reiterated by analysts at Robert W. Baird. Looking at the stock's movement on the chart, Coherus Biosciences, Inc. recorded a 52-week high of $31.98. Zacks Investment Research upgraded Coherus Biosciences from a "hold" rating to a "buy" rating and set a $26.00 price objective on the stock in a research note on Tuesday, February 14th. BMO Capital Markets started coverage on shares of Coherus Biosciences in a research note on Friday, May 5th. Further, analysts have a 12 month target price of $5.72 on company shares. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold.

Google VR Headsets Will Be Untethered And Fully Tracked
They will also be able to virtually place the product in the living space to get them an idea of how the product could look like. The new devices won't require a phone or PC and will be made available to consumers later this year.

11/28/2016 - Standpoint Research began new coverage on Coherus BioSciences, Inc. giving the company a "speculative buy" rating.

The share price of the company (CHRS) was up +2.94%, with a high of 24.50 during the day and the volume of Coherus BioSciences, Inc. shares traded was 984966. The firm has a 50 day moving average price of $20.18 and a 200 day moving average price of $24.52. This company shares are 14.09% off its target price of $27.13 and the current market capitalization stands at $18.05B.

Coherus Biosciences (NASDAQ:CHRS) last announced its earnings results on Monday, May 8th. The biotechnology company reported ($1.54) EPS for the quarter, meeting analysts' consensus estimates of ($1.54). Given that its average daily volume over the 30 days has been 0.48 million shares a day, this signifies a pretty significant change over the norm. Equities research analysts expect that Coherus Biosciences will post ($5.13) EPS for the current year. If you are accessing this story on another domain, it was stolen and republished in violation of global copyright and trademark legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2017/05/16/coherus-biosciences-chrs-getting-somewhat-positive-media-coverage-analysis-shows-updated-updated-updated.html. A simple moving average (SMA) is an arithmetic moving average calculated by adding the closing price of the security for a number of time periods and then dividing this total by the number of time periods. The sale was disclosed in a filing with the SEC, which is available at this link. Pictet Asset Management Ltd. boosted its stake in shares of Coherus Biosciences by 0.3% in the first quarter.

Brocade Communications Systems, Inc. (BRCD) Receives $10.25 Average PT from Analysts
Acrospire Investment Management LLC increased its stake in shares of Brocade Communications Systems by 20.4% in the third quarter. Analysts are expecting EPS growth rates to be at -35.20% this quarter and EPS estimate for next year reflect a 4.36% growth rate.

In other news, insider Alan C. Herman sold 11,333 shares of the company's stock in a transaction on Monday, April 3rd. Finally, Tudor Investment Corp Et Al increased its position in shares of Coherus Biosciences by 34.9% in the fourth quarter. Legal & General Group Plc now owns 8,295 shares of the biotechnology company's stock valued at $173,000 after buying an additional 1,137 shares during the last quarter.

Coherus BioScience (CHRS) is rising Wednesday, after a patent trial ruled in its favor of and against AbbVie (ABBV) in a lawsuit over Humira, the rheumatoid arthritis drug that accounts for almost two-thirds of AbbVie's sales. State Board of Administration of Florida Retirement System now owns 14,589 shares of the biotechnology company's stock worth $411,000 after buying an additional 130 shares during the last quarter. Finally, Croft Leominster Inc. purchased a new stake in shares of Coherus Biosciences during the third quarter valued at $401,000. Rock Springs Capital Management LP now owns 467,500 shares of the biotechnology company's stock worth $12,520,000 after buying an additional 67,500 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Coherus Biosciences during the first quarter worth about $319,000. Institutional investors own 64.52% of the company's stock.

In recent action, Coherus Biosciences, Inc. The Company is engaged in the business of developing and commercializing biosimilar products.

United States airstrikes in Syria 'completely unacceptable', Russian Federation says
Syrian government forces secure a road for a military convoy in the desert area near the border with Jordan and Iraq, May 10, 2017.